Wall Street Zen Downgrades Lifevantage (NASDAQ:LFVN) to Hold

Lifevantage (NASDAQ:LFVN) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Friday.

Separately, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Lifevantage in a research report on Saturday, September 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $30.50.

Lifevantage Price Performance

Shares of NASDAQ:LFVN opened at $9.48 on Friday. Lifevantage has a fifty-two week low of $9.44 and a fifty-two week high of $27.38. The business has a 50-day moving average of $12.13 and a two-hundred day moving average of $12.81. The stock has a market capitalization of $120.30 million, a P/E ratio of 12.81 and a beta of 0.26.

Lifevantage (NASDAQ:LFVN) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.17 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.17. Lifevantage had a return on equity of 33.75% and a net margin of 4.29%.The company had revenue of $55.11 million during the quarter, compared to analysts’ expectations of $57.93 million. During the same quarter in the previous year, the firm earned $0.14 earnings per share. Lifevantage has set its FY 2026 guidance at 1.000-1.15 EPS.

Insiders Place Their Bets

In other Lifevantage news, Director Michael A. Beindorff sold 4,125 shares of Lifevantage stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $11.44, for a total transaction of $47,190.00. Following the sale, the director directly owned 22,858 shares of the company’s stock, valued at approximately $261,495.52. The trade was a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 21.95% of the company’s stock.

Institutional Investors Weigh In On Lifevantage

A number of institutional investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. boosted its holdings in Lifevantage by 780.3% during the second quarter. Osaic Holdings Inc. now owns 14,270 shares of the company’s stock valued at $187,000 after purchasing an additional 12,649 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Lifevantage by 68.1% during the second quarter. Squarepoint Ops LLC now owns 70,507 shares of the company’s stock valued at $922,000 after purchasing an additional 28,574 shares in the last quarter. Evergreen Capital Management LLC acquired a new stake in Lifevantage during the second quarter valued at approximately $379,000. Wasatch Advisors LP boosted its holdings in Lifevantage by 6.6% during the second quarter. Wasatch Advisors LP now owns 446,341 shares of the company’s stock valued at $5,838,000 after purchasing an additional 27,765 shares in the last quarter. Finally, Man Group plc boosted its holdings in Lifevantage by 72.5% during the second quarter. Man Group plc now owns 53,098 shares of the company’s stock valued at $695,000 after purchasing an additional 22,319 shares in the last quarter. 35.32% of the stock is owned by institutional investors and hedge funds.

Lifevantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.